Organic Active Ingredients TRIZ Cases

Modified trinucleotide caps prevent unwanted initiation while raising transcription yields and improving intracellular mRNA stability.

This case combines lipid nanoparticles, self-amplifying RNA, and IL-12 to link tumor-site cell death with systemic immunity.

This case combines alternating electric fields with IGF1R, JNK, RPS6, or ERK inhibitors to counter resistance and improve efficacy.

Localized chemical modifications and polymorphic forms tailor RTA 408 activity across inflammatory and oxidative stress conditions.

This case uses excipient and particle adjustments to align baclofen and M1 exposure ratios with approved tablets.

Targeted ubiquitin-proteasome degradation of G12D mutant KRAS offers a selective treatment approach for difficult pancreatic cancer cases.

Substituted carbazole compounds target TLR7/8/9 signaling, addressing uncontrolled inflammation with selective immunomodulation.

This case uses 3′SL and 6′SL to reduce macrophage inflammation and IL-1β, IL-6, and TNF-α signaling in persistent pain.

SAR-driven DRG-BCL2-1 modifies substituents and pharmacophores to address BCL-2 mutation resistance while supporting apoptosis.

Selective thiazole compounds inhibit KIT to reduce systemic mast cell activity.

This case uses BA-1049 (R) and active metabolites to achieve potent ROCK2 selectivity for neurological treatment with fewer side effects.

This case combines benzodiazepine and pyrazole structures to pair potent RSV inhibition with favorable pharmacokinetic properties.

A three-component Ras–cyclophilin A complex creates a binding pocket that blocks downstream signaling and supports cancer therapy research.

A biodegradable risperidone copolymer forms an excisable implant after injection, supporting 21–90-day release with minimal initial burst.

Formula I pteridinones target WFS1 to induce calcium release, ER stress, and cancer cell death in proliferative disorders.

This case uses carbazate-modified PVAC to bind carbonyls, induce apoptosis, and reduce tumor growth without membrane disruption.

This case uses 2–8 mg daily with oleic acid complexes for sustained delivery and reduced fatigue and sedation during antiemetic treatment.

This case uses niraparib maintenance after platinum chemotherapy to delay recurrence, including in patients without BRCA mutations.

This case combines niraparib, low-dose prednisone, and ADT to inhibit tumor growth in high-risk mCRPC with DNA repair anomalies.

The case varies ecteinascidin 736 substituents to balance tumor selectivity, pharmacokinetics, antitumor activity, and systemic toxicity.

This case uses tailored aminopyrimidine substituents to inhibit EGFR mutants and address resistance with less wild-type activity.

This case uses excipients in solid adagrasib tablets to improve stability, drug release, and bioavailability while limiting GI effects.

A microjet-reactor nanoparticle dispersion reduces lipid load and microbial growth risks while preserving immediate release.

This case uses salvianolic acid B to lower GCS and GM3 synthase levels, promoting ceramide-mediated apoptosis in TNBC cells.

A single evening dose delays and extends methylphenidate release for ADHD coverage.

This case shows how selected organic-acid counterions limit trimetazidine nitrosamine formation in the presence of nitrites.

This case uses ALK2 inhibition to lower hepcidin, restore iron availability, and address anemia beyond limited ESA response.

This case varies 6-aryl substituents in a quinoline-piperidine scaffold to address inadequate treatment for drug-resistant tuberculosis.

This case develops tunable 15-PGDH inhibitor compounds to increase substrate levels across fibrosis, inflammation, and other diseases.

This case combines defined-structure Ganoderma polysaccharides with chemotherapy to limit toxic effects and support tumor control.

This formulation combines cellulose and disintegrants to deliver up to 80% dissolution in 15 minutes with storage stability.

A shellac, alcohol, and surfactant banding composition forms an acid-resistant seal that preserves two-piece capsule integrity.

This case converts Type A oxazole crystals to Type B, using polymorphism to improve thermal stability and preserve PDE4 activity.

This case uses plant-derived compounds to activate HNF4α, improving insulin expression and lipid clearance for metabolic disorders.

This case combines SIK3 inhibition with TRAIL signaling to overcome apoptosis resistance in proliferative cancer cells.

Hydrophobic groups, vinyl phosphonate, and modified backbones improve oligonucleotide stability and delivery for mRNA reduction.

This case couples hydrophobic fragments to DP7, forming micelles that reduce red blood cell lysis and support intravenous use.

Tegoprazan protects the stomach while preserving clopidogrel's antiplatelet effect.

Enfumafungin derivatives inhibit glucan synthesis while reaching bone and joint tissues for long-term oral treatment.

RNA interference targets XDH mRNA to reduce uric acid, offering an option for gout patients with chronic kidney disease.

This case defines a 150–225 mg diclofenac sodium adhesive patch applied once daily to address unclear dosing and cancer pain relief.

This case uses GDF/BMP antagonists to address vascular remodeling and muscularization while reducing pulmonary hypertension severity.

This topical composition combines low levels of erythrulose and retinyl acetate to inhibit microbes and preserve skin homeostasis.

This case uses cyclic dinucleotide partial agonists to activate type I interferon responses while limiting toxicity during cancer therapy.

This case shows how tetrazole derivatives improve TRPA1 potency, liver stability, bioavailability, and dosing intervals.

A high-load colesevelam composition releases in the ileum and colon, reducing dosing frequency and upper-GI drug interactions.

A heat-treated aqueous ophthalmic suspension maintains uniform particle dispersion, supporting consistent dosing with fewer shakes.

A novel galactose-glycerol phosphate EPS promotes interferon-γ production.

This case combines LPPO with polycaprolactone nanofibers to avoid rapid diffusion and sustain enzyme-controlled topical release.

This case combines a heterocyclidene acetamide derivative with co-actives and surfactants to improve redispersion in eye drops.